Rac family small GTPase 1Genealiases: MIG5 · MRD48 · Rac-1 · TC-25 · p21-Rac1
Q-omics provides the consensus-scored RAC1 profile across patient tissues and cancer cell-line models. RAC1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RAC1 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, RAC1 protein abundance shows 26,749 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight MESO, KIRC, and PDAC as cancer lineages where RAC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAC1 survival associations across molecular data types. RAC1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAC1 RNA expression–survival associations across cancer types. High RAC1 expression shows unfavorable associations in MESO, ACC, LIHC, LUAD, PAAD and UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RAC1 RNA expression.
This table summarizes RAC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RAC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAC1 shows higher tumor expression in KIRC, HNSC, LIHC, KIRP, STAD and LUAD. The KIRC box plot shows higher RAC1 RNA expression in tumor versus normal tissue (log2 FC = +0.442, t-test p < 0.001).
This table shows molecular features associated with RAC1 in patient tissues and cancer cell lines. In patient samples, RAC1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LUNG_NSCLC_LUAD.
